214 related articles for article (PubMed ID: 32803316)
1. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.
Guo F; Song X; Li Y; Guan W; Pan W; Yu W; Li T; Hsieh E
Osteoporos Int; 2021 Feb; 32(2):321-332. PubMed ID: 32803316
[TBL] [Abstract][Full Text] [Related]
2. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
[TBL] [Abstract][Full Text] [Related]
4. Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals.
Guan W; Pan W; Yu W; Cao W; Lin Q; Zhang Z; Song X; Li Y; Tian J; Xu Y; Li T; Hsieh E
Arch Osteoporos; 2021 Feb; 16(1):41. PubMed ID: 33624129
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
Kiweewa Matovu F; Kiwanuka N; Nabwana M; Scholes D; Musoke P; Glenn Fowler M; Beksinska ME; Pettifor JM; Brown TT;
Lancet Glob Health; 2022 May; 10(5):e694-e704. PubMed ID: 35427526
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
[TBL] [Abstract][Full Text] [Related]
7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
10. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
11. The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
Alvarez E; Campbell L; Tinago W; Garcia-Leon A; Walsh I; Brady JJ; Burling K; Noe S; Neuville MF; Jouret F; Jamshidian F; Graham H; Rhee M; Mallon PW; Post FA
Antivir Ther; 2022 Aug; 27(4):13596535221094898. PubMed ID: 36000318
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.
Liu AY; Vittinghoff E; Sellmeyer DE; Irvin R; Mulligan K; Mayer K; Thompson M; Grant R; Pathak S; O'Hara B; Gvetadze R; Chillag K; Grohskopf L; Buchbinder SP
PLoS One; 2011; 6(8):e23688. PubMed ID: 21897852
[TBL] [Abstract][Full Text] [Related]
14. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
15. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
[TBL] [Abstract][Full Text] [Related]
16. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR;
Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069
[TBL] [Abstract][Full Text] [Related]
17. Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy.
Guan WM; Pan W; Yu W; Cao W; Lin Q; Zhang ZZ; Song XJ; Li YL; Tian JP; Xu Y; Li TS; Hsieh E
J Orthop Translat; 2021 Jul; 29():72-77. PubMed ID: 34094860
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
[TBL] [Abstract][Full Text] [Related]
19. Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.
Hamzah L; Samarawickrama A; Campbell L; Pope M; Burling K; Fisher M; Gilleece Y; Walker-Bone K; Post FA
AIDS; 2015 Sep; 29(14):1785-1792. PubMed ID: 26372384
[TBL] [Abstract][Full Text] [Related]
20. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
